ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- The impact of advanced glycation end products and their receptors on the development and prognosis of colorectal cancer.BMC cancer · 2026Pooled it
- Association between hOGG1 polymorphism rs1052133 and gastric cancer.Oncotarget · 2017Pooled it
- Genetically lowered concentrations of circulating sRAGE might cause an increased risk of cancer: Meta-analysis using Mendelian randomization.The Journal of international medical research · 2016Pooled it
- Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies.Medical oncology (Northwood, London, England) · 2015Pooled it
- Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development.Frontiers in oncology · 2020Review
- Determination ofDisease markers · 2019Article
- RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.Hormones & cancer · 2018Review
- A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.Oncotarget · 2017Article
- Effect ofCancer cell international · 2017Article
- The association analysis of hOGG1 genetic variants and gastric cancer risk in a Chinese population.Oncotarget · 2016Article
- Effects of RAGE Gene Polymorphisms on the Risk and Progression of Hepatocellular Carcinoma.Medicine · 2015Article
- RAGE gene polymorphism and environmental factor in the risk of oral cancer.Journal of dental research · 2015Article
- Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.Advances in cancer research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The receptor for advanced glycation end products (RAGE) has previously been suggested to stimulate the growth, survival, and metastatic spread of colorectal cancers (CRC). The genetic variant Gly82Ser of RAGE influences its function and is associated with an increased risk of gastric cancer and multiple sclerosis. To investigate the association between the Gly82Ser polymorphisms of RAGE and the risk of CRC, 90 CRC patients and 78 control subjects with benign polyps were genotyped and the results were analyzed using the SPSS statistical software.In comparing with the control group, the CRC group has a higher ratio in the Gly82Ser polymorphism. The odds ratio (OR) for heterozygous GS is 2.037 (95% CI 1.207-3.438); the OR for carriers with the S allele (SS) is 3.32 (95% CI 0.94-11.65). Further stratification analysis of the correlation of the Gly82Ser polymorphism with tumor stages and differentiation indicated that CRC patients with TNM (III + IV) and/or patients with poorly differentiated colorectal cancer have an elevated Gly82Ser polymorphism. The OR for TNM (III + IV) is 3.575, 95% CI 1.495-8.550, and the OR for poorly differentiated is 3.580, 95% CI 1.390-9.217. In conclusion, the RAGE gene Gly82Ser polymorphism may confer not only an increased risk of CRC but also an increased invasion of CRC in the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.